Correcting a missing immune enzyme using an mRNA cell therapy
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy, Infections clinical trials.
This early-phase trial tests whether an mRNA-based treatment can correct a key immune problem in people with chronic granulomatous disease (CGD). It may help your immune cells work better against infections, but this is mainly to check safety and early signs of benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a male age 18 to 75
- Your CGD diagnosis is confirmed by specific lab tests (blood protein testing and/or genetic testing)
- You have a doctor you can contact at home for follow-up visits
- You can understand the study and sign consent
- You agree to use contraception if pregnancy is possible from your sex during screening through 3 months after infusion
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an intensive stem cell transplant approach for people with chronic granulomatous disease (CGD). The study aims to improve outcomes by preparing the body for a donor stem cell graft and using immune “brakes” to reduce immune problems.
This trial tests a new gene therapy for people with a specific type of chronic granulomatous disease (p47 CGD). The treatment uses your own blood stem cells, which are modified in a lab to help your body fight infections better. It is for people who do not have a matched stem cell donor and have had serious infections.
This trial tests a lentiviral gene therapy to improve immune function in people with CGD, a condition where the body can’t fight certain infections well. It may help by addressing the underlying genetic problem, but it also requires a procedure to collect immune cells and special “conditioning” medicines beforehand.
This trial tests a new gene editing treatment called PM359 for people with a specific type of chronic granulomatous disease (CGD) caused by a delGT mutation in the NCF1 gene. The goal is to see if it's safe and helps fight infections and inflammation.
This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.
This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.
Hear when a new Chronic Granulomatous Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.